DOSE DEPENDENT SUPPRESSION OF MINERALOCORTICOID METABOLISM BY DIFFERENT HEPARIN FRACTIONS

被引:23
作者
SIEBELS, M
ANDRASSY, K
VECSEI, P
SEELIG, HP
BACK, T
NAWROTH, P
WEBER, E
机构
[1] UNIV HOSP HEIDELBERG,DEPT NEUROL,W-6900 HEIDELBERG,GERMANY
[2] UNIV HOSP HEIDELBERG,DEPT CLIN PHARMACOL,W-6900 HEIDELBERG,GERMANY
[3] INST IMMUNOL,W-7500 KARLSRUHE,GERMANY
关键词
HEPARIN; LMWH; ALDOSTERONE; HYPERKALEMIA;
D O I
10.1016/0049-3848(92)90301-P
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
One neglected side effect of heparin therapy is the inhibition of adrenal aldosterone production leading to occasionally life-threatening hyperkalaemia. This is only reported with (therapeutic) high doses (greater-than-or-equal-to 20.000 IU). The complex interplay of mineralocorticoid metabolites was studied in 29 subjects with unfractionated (UFH) and low molecular weight heparin (LMWH). Both heparins altered mineralocorticoid metabolism in a dose dependent manner. Whereas no effect was observed with UFH 2x5000 IU sc/day or LMWH 2500 a FXa U sc/day, higher doses significantly suppressed aldosterone and 18-hydroxycorticosterone production in plasma and urine. Three out of seven patients receiving UFH 3x7500 IU sc/day developed hyperkalaemia. This study shows the threshold dosage of UFH leading to suppression of mineralocorticoid metabolism in man and provides information that LMWH as well as UFH can suppress mineralocorticoid production. With respect to therapeutic implications it is important that LMWH at 2500 a FXa U sc/d had no effect on mineralocorticoid metabolism in contrast to UFH at a dosage currently used for prevention of thromboembolism (3x5000 IU sc/d).
引用
收藏
页码:467 / 473
页数:7
相关论文
共 17 条
[1]   LOW-MOLECULAR-WEIGHT HEPARIN ONCE DAILY COMPARED WITH CONVENTIONAL LOW-DOSE HEPARIN TWICE DAILY - A PROSPECTIVE DOUBLE-BLIND MULTICENTER TRIAL ON PREVENTION OF POSTOPERATIVE THROMBOSIS [J].
BERGQVIST, D ;
BURMARK, US ;
FRISELL, J ;
HALLBOOK, T ;
LINDBLAD, B ;
RISBERG, B ;
TORNGREN, S ;
WALLIN, G .
BRITISH JOURNAL OF SURGERY, 1986, 73 (03) :204-208
[2]   INHIBITION BY HEPARINOID OF ALDOSTERONE BIOSYNTHESIS IN MAN [J].
CONN, JW ;
ROVNER, DR ;
COHEN, EL ;
ANDERSON, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1966, 26 (05) :527-+
[3]   ALDOSTERONE DIAGNOSIS IN HYPERTENSION - COMPARATIVE EVALUATION OF RADIOIMMUNOASSAYS FOR URINARY ALDOSTERONE AND CORTICOSTERONE-18-OH [J].
CONNOLLY, TM ;
VECSEI, P ;
HAACK, D ;
KOHL, KH ;
ABDELHAMID, S ;
AMMENTI, A .
KLINISCHE WOCHENSCHRIFT, 1978, 56 :173-181
[4]   EFFECT OF HEPARIN ON ALDOSTERONE SECRETION ANDMETABOLISM IN PRIMARY ALDOSTERONISM (1) [J].
FORD, HC ;
BAILEY, RE .
STEROIDS, 1966, 7 (01) :30-&
[5]   APPLICATION OF A RADIOIMMUNOASSAY FOR ANGIOTENSIN I TO PHYSIOLOGIC MEASUREMENTS OF PLASMA RENIN ACTIVITY IN NORMAL HUMAN SUBJECTS [J].
HABER, E ;
KOERNER, T ;
PAGE, LB ;
KLIMAN, B ;
PURNODE, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1969, 29 (10) :1349-+
[6]  
JAQUES LB, 1967, PHARM HEPARIN HEPARI
[7]  
KLOPPENBORG PWC, 1975, ACTA MED SCAND, V197, P99
[8]  
KUTYRINA I M, 1987, Nephrology Dialysis Transplantation, V2, P219
[9]   HEPARIN COFACTOR ACTIVITY MEASURED WITH AN AMIDOLYTIC METHOD [J].
ODEGARD, OR ;
LIE, M ;
ABILDGAARD, U .
THROMBOSIS RESEARCH, 1975, 6 (04) :287-294
[10]  
SADAHIDE A, 1988, ACTA ENDOCRINOL-COP, V119, P367